Thrombogenics Awarded €1.1 Million IWT Research Grant
News Feb 05, 2015
ThromboGenics NV has announced that it has been awarded a €1.1 million research grant from the Flemish agency for Innovation by Science and Technology (IWT).
The grant will be used by Thrombogenics to fund the on-going research to further elucidate the pharmacological effects ocriplasmin is exerting in the back of the eye following intravitreal (IVT) injection.
Dr Patrik De Haes, CEO of ThromboGenics comments: “The award of this grant from IWT supports our commitment to gain further insight into JETREA®s action in the vitreo-retinal interface. In conjunction with a growing body of real world and clinical trial data, we hope that the continual efforts at the preclinical research level will contribute to an improved awareness and acceptance of JETREA® by physicians as a first in class pharmaceutical treatment for symptomatic VMA.”
Algorithm Predicts Life Expectancy After Heart AttackNews
A new algorithm developed by UCLA researchers more accurately predicts which people will survive heart failure, and for how long, whether or not they receive a heart transplant. The algorithm would allow doctors to make more personalized assessments of people who are awaiting heart transplants, which in turn could enable health care providers to make better use of limited life-saving resources and potentially reduce health care costs.
Plug-and-Play Diagnostic Devices DevelopedNews
Researchers at MIT’s Little Devices Lab have developed a set of modular blocks that can be put together in different ways to produce diagnostic devices. These “plug-and-play” devices, which require little expertise to assemble, can test blood glucose levels in diabetic patients or detect viral infection, among other functions.READ MORE